Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-03: A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of recurrent or refractory CD19+ leukemia
- Adequate performance status
- Able to tolerate apheresis, including placement of temporary apheresis line if required
- Adequate renal, liver, cardiac, and respiratory function
- Adequate absolute lymphocyte count
- HIV negative; Hepatitis B and C negative within 3 months prior to enrollment.
Exclusion Criteria:
- Evidence of active clinically significant CNS dysfunction
- Evidence of active malignancy other than CD19+ malignancy
- Evidence of active GVHD, or on immunosuppressive GVHD therapy within 4 weeks prior to enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cohort A
Participants will receive CD19-targeting CAR T cells.
Participants who have a total CD19 antigen load in bone marrow of <15% will be assigned to Cohort A, to receive up to 6 T-APC treatments.
|
Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
Other Names:
|
|
Experimental: Cohort B
Participants will receive CD19-targeting CAR T cells.
Participants for whom laboratory testing on Study Day 14 indicates they are at risk for early loss of CAR T cells will be assigned to Cohort B to receive up to 6 T-APC treatments.
If laboratory testing prior to planned T-APC treatment indicates loss of CAR-T cells, participants may move to Cohort C.
|
Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
Other Names:
|
|
Experimental: Cohort C
Participants will receive CD19-targeting CAR T cells.
Participants for whom laboratory testing shows loss of CAR T cells within 6 months will be assigned to Cohort C. They will receive another CAR T cell infusion followed by up to 6 T-APC treatments.
|
Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
Other Names:
|
|
Experimental: Cohort D
Participants will receive CD19-targeting CAR T cells.
Participants who do not meet assignment rules for Cohorts A, B, or C will be followed after CAR T cell infusion in Cohort D.
|
Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The adverse events associated with one or multiple CD19t T-APC product infusions will be assessed.
Time Frame: up to 6 months
|
Type, frequency, severity, and duration of adverse events will be summarized
|
up to 6 months
|
|
Determine the feasibility of deriving and administering a CD19t T-APC product
Time Frame: 28 days
|
Proportion of products successfully manufactured and infused
|
28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quantification of changes in the number of CAR T cells in peripheral blood before and after receiving CD19t T-APCs
Time Frame: 6 months
|
Multiparameter Flow Cytometry (MPF) from peripheral blood as a measure of magnitude and presence of CAR T cells before and after a dose of T-APCs
|
6 months
|
|
Duration of B cell aplasia in CD19t T-APC treated patients
Time Frame: up to 5 years
|
MPF from peripheral blood as a measure of B cell aplasia
|
up to 5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Colleen Annesley, MD, Seattle Children's Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Leukemia, Lymphoid
- Hemic and Lymphatic Diseases
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Investigative Techniques
- Therapeutics
- Biological Therapy
- Immunologic Techniques
- Immunomodulation
- Adoptive Transfer
- Immunization, Passive
- Immunization
- Immunotherapy
- Immunotherapy, Adoptive
Other Study ID Numbers
Other Study ID Numbers
- PLAT-03
Plan for Individual participant data (IPD)
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.